Rapamycin (Sirolimus) for Alzheimer's Disease
Also known as: Sirolimus
mTOR hyperactivation reduces autophagy, contributing to amyloid and tau accumulation in Alzheimer's. Rapamycin restores autophagic clearance.
Mechanism of Action
In Alzheimer's, mTOR hyperactivation suppresses autophagy, leading to accumulation of amyloid-beta and phosphorylated tau. Rapamycin restores autophagic flux, promotes clearance of protein aggregates, reduces neuroinflammation (through microglial autophagy), and may improve cerebrovascular function.
General mechanism: mTORC1 inhibitor via FKBP12 binding. Promotes autophagy, suppresses cap-dependent translation, reduces senescent cell accumulation.
Current Evidence
Preclinical models show rapamycin reduces amyloid and tau pathology, improves cognition, and extends lifespan. The PEARL trial and translational studies aim to establish human neurological benefits. Safety data from transplant recipients informs dosing.
Clinical Status: Preclinical evidence strong for Alzheimer's. PEARL trial (longevity) underway. No Alzheimer's-specific clinical trials yet.
Safety Profile
Immunosuppression at high doses. Mouth sores, metabolic effects (lipids, glucose). Low-dose intermittent regimens better tolerated.
Key Research Questions
- What rapamycin dosing regimen optimizes brain autophagy without excessive immunosuppression?
- Can rapamycin combination with anti-amyloid antibodies enhance plaque clearance?
- Does rapamycin prevent or slow Alzheimer's in at-risk populations (APOE4 carriers)?
Frequently Asked Questions
Is rapamycin safe for cancer patients?
Rapamycin (sirolimus) is FDA-approved as an immunosuppressant and has been studied in cancer clinical trials. Its mTOR-inhibiting mechanism induces autophagy and suppresses tumor growth. Side effects include immunosuppression and metabolic changes. Always discuss with your oncologist.
What is the rapamycin dosage for longevity?
Longevity-focused protocols typically use 3-6mg once weekly (intermittent dosing), which differs from the daily immunosuppressive dose. The PEARL trial is studying 5mg weekly. Low-dose intermittent rapamycin aims to activate autophagy without chronic immunosuppression.
Rapamycin vs metformin for anti-aging
Rapamycin inhibits mTOR to promote autophagy and cellular recycling. Metformin activates AMPK to improve metabolic health. They target complementary pathways and some researchers propose combining them. Rapamycin has stronger preclinical longevity data; metformin has a longer safety record.